Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Stephen J. Russell, Glen N. Barber
Cancer Cell (2018) Vol. 33, Iss. 4, pp. 599-605
Open Access | Times Cited: 206

Showing 1-25 of 206 citing articles:

CD8+ T cell differentiation and dysfunction in cancer
Mary Philip, Andrea Schietinger
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 209-223
Open Access | Times Cited: 695
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Jian Liu, Minyang Fu, Manni Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 495
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
Lu Zhang, Yi Liao, Liling Tang
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 440
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes, Gaëlle Vandermeulen, Véronique Préat
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 335
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
Zong Sheng Guo, Binfeng Lu, Zongbi Guo, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 252
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Meijun Zheng, Jianhan Huang, Aiping Tong, et al.
Molecular Therapy — Oncolytics (2019) Vol. 15, pp. 234-247
Open Access | Times Cited: 250
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodríguez-García, Asís Palazón, Estela Noguera-Ortega, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 243
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Hanne Locy, Sven de Mey, Wout de Mey, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 214
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Aurélien Marabelle, Robert Hans Ingemar Andtbacka, Kevin J. Harrington, et al.
Annals of Oncology (2018) Vol. 29, Iss. 11, pp. 2163-2174
Open Access | Times Cited: 181
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
Guan Wang, Xi Kang, Katherine Chen, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 175
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Yaomei Tian, Daoyuan Xie, Yang Li
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 171
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade
Shinsuke Nakao, Yukinori Arai, Mamoru Tasaki, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 526
Open Access | Times Cited: 155
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment
Tao Shi, Xueru Song, Yue Wang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 140
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 137
mRNA vaccines for cancer immunotherapy
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 97
Tertiary lymphoid structures in anticancer immunity
Jean‐Luc Teillaud, Ana Houel, Marylou Panouillot, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 9, pp. 629-646
Closed Access | Times Cited: 35
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh, et al.
Small (2024) Vol. 20, Iss. 35
Open Access | Times Cited: 26
Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy
Simona Ruxandra Volovăț, Dragoş Viorel Scripcariu, Ingrid-Andrada Vasilache, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1180-1180
Open Access | Times Cited: 22
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside
Florent Peyraud, Jean‐Philippe Guégan, Lucile Vanhersecke, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100546-100546
Closed Access | Times Cited: 3
DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Alireza Shariati, Arya Khezrpour, Fatemeh Sadat Shariati, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 3
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Hong Jae Chon, Won Suk Lee, Hannah Yang, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 5, pp. 1612-1623
Open Access | Times Cited: 143
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Sònia Guedan, Ramón Alemany
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 128
Virus-Based Immunotherapy of Glioblastoma
Miika Martikainen, Magnus Essand
Cancers (2019) Vol. 11, Iss. 2, pp. 186-186
Open Access | Times Cited: 128
Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance
Dayana B. Rivadeneira, Kristin DePeaux, Yiyang Wang, et al.
Immunity (2019) Vol. 51, Iss. 3, pp. 548-560.e4
Open Access | Times Cited: 121
Recent updates on cancer immunotherapy
Ming Liu, Fukun Guo
Precision Clinical Medicine (2018) Vol. 1, Iss. 2, pp. 65-74
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top